Over the forecast period, rising government attempts to combat malaria are anticipated to fuel market expansion for malaria vaccines worldwide. For instance, in October 2021, the World Health Organization (WHO) advised that children in sub-Saharan Africa and other areas with moderate to high P. falciparum malaria transmission widely use the RTS,S/AS01 (RTS,S) malaria vaccine. The advice was based on the outcomes of a trial programme that has been running in Ghana, Kenya, and Malawi and has helped more than 900,000 kids since 2019.
Global Malaria Vaccines Market is estimated to be valued at US$ 41.08 million in 2022 and is expected to exhibit a CAGR of 29.6% during the forecast period (2022-2030).
Top Companies in the Malaria Vaccines Industry:
1. GlaxoSmithKline plc
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. GSK plc and Wave Life Sciences Ltd in December, 2022 announced a strategic collaboration to advance oligonucleotide therapeutics, including Wave’s preclinical RNA editing programme targeting alpha-1 antitrypsin deficiency (AATD), WVE-006.
2. Nobelpharma
Nobelpharma was founded in 2003 and projects of drugs and medical devices for unmet medical needs. It has headquarters situated in Chuo-ku, Tokyo. In February, 2023 Nobelpharma announced that the company has launched NOBELZIN® Granules 5% for Wilson's disease (copper absorption inhibitor) and hypozincemia.